Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm





    Chief Complaint


    Organ System


    Patent Pending

    Modified Asthma Predictive Index (mAPI)

    Predicts future asthma in pediatric patients.


    This score applies to pediatric patients ≤3 years old.
    When to Use
    Why Use

    Children ≤3 years old with known wheezing.

    • The Modified Asthma Predictive Index (mAPI) provides a method for predicting likelihood of a later asthma diagnosis.
    • It is only applicable in young children with 4 or more episodes of wheezing per year.
    • The mAPI's predictive ability depends heavily on prevalence of asthma in the general population.

    A standardized score for determining which children are at higher risk for development of asthma may improve care or disease detection, possibly better than the Asthma Predictive Index (API).

    Major Criteria
    Minor Criteria


    Please fill out required fields.

    Next Steps
    Creator Insights


    Unfortunately, while the mAPI was used successfully to identify high asthma risk children in a randomized trial, there was no long term benefit found from inhaled corticosteroids on the development of asthma or lung function.


    Positive mAPI defined by:

    • ≥4 episodes of wheezing per year, AND
    • ≥1 major criteria OR ≥2 minor criteria

    Facts & Figures

    Sensitivity and specificity for positive predictions of asthma by year of life

    Year Sensitivity (95% CI) Specificity (95% CI)
    Age 6 asthma diagnosis
    1 11% (4.2–19) 98% (96–100)
    2 12% (4.2–19) 99% (98–100)
    3 17% (8.4–25) 99% (98–100)
    Age 8 asthma diagnosis
    1 8.2% (2.2–14) 98% (97–100)
    2 11% (3.9–18) 99% (98–100)
    3 19% (8.8–25) 100% (99–100)
    Age 11 asthma diagnosis
    1 11% (3.6–18) 98% (95–100)
    2 11% (3.6–19) 98% (96–100)
    3 19% (9.3–28) 99% (97–100)
    Dr. Timothy S. Chang

    About the Creator

    Timothy S. Chang, MD, PhD, is a neurology resident at UCLA. He received his PhD in Clinical Investigation with a concentration in biomedical informatics in the Institute for Clinical and Translational Research from the University of Wisconsin. He has published many papers on topics including Alzheimer’s treatment and respiratory disease diagnosis.

    To view Dr. Timothy S. Chang's publications, visit PubMed